Abstract
Objective
Patients and Methods
Results
Conclusion
Abbreviations and Acronyms:
CMS (Centers for Medicare and Medicaid Services), eGFR (estimated glomerular filtration rate), ESRD (end-stage renal disease), ICD-9-CM (International Classification of Diseases), Ninth Revision (Clinical Modification), IQR (interquartile range), KPSC (Kaiser Permanente Southern California), PS (prognostic score), USRDS (United States Renal Data System), VA (Veterans Affairs)Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Mayo Clinic ProceedingsReferences
- US Renal Data System 2016 Annual Data Report: Epidemiology of Kidney Disease in the United States [published correction appears in Am J Kidney Dis. 2017;69(5):712].Am J Kidney Dis. 2017; 69: A7-A8
- Supportive care: time to change our prognostic tools and their use in CKD.Clin J Am Soc Nephrol. 2016; 11: 1892-1901
- Supportive care: communication strategies to improve cultural competence in shared decision making.Clin J Am Soc Nephrol. 2016; 11: 1902-1908
- Incremental and infrequent hemodialysis: a new paradigm for both dialysis initiation and conservative management.Panminerva Med. 2017; 59: 188-196
- Incremental hemodialysis, residual kidney function, and mortality risk in incident dialysis patients: a cohort study.Am J Kidney Dis. 2016; 68: 256-265
- Dietary management of incremental transition to dialysis therapy: once-weekly hemodialysis combined with low-protein diet [published correction appears in J Ren Nutr. 2017;27(1):74].J Ren Nutr. 2016; 26: 352-359
- A clinical risk prediction tool for 6-month mortality after dialysis initiation among older adults.Am J Kidney Dis. 2017; 69: 568-575
- Advance prediction of early death in patients starting maintenance dialysis.Am J Kidney Dis. 1994; 23: 836-845
- Prediction of early death in end-stage renal disease patients starting dialysis.Am J Kidney Dis. 1997; 29: 214-222
- Predicting early death among elderly dialysis patients: development and validation of a risk score to assist shared decision making for dialysis initiation.Am J Kidney Dis. 2015; 66: 1024-1032
- Development of a risk stratification algorithm to improve patient-centered care and decision making for incident elderly patients with end-stage renal disease.Kidney Int. 2015; 88: 1178-1186
- French Renal Epidemiology and Information Network (REIN) Registry. A clinical score to predict 6-month prognosis in elderly patients starting dialysis for end-stage renal disease.Nephrol Dial Transplant. 2009; 24: 1553-1561
- Predicting mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry.Am J Kidney Dis. 2011; 57: 894-902
- An improved comorbidity index for outcome analyses among dialysis patients.Kidney Int. 2010; 77: 141-151
- Prediction of mortality in the first two years of hemodialysis: results from a validation study.Blood Purif. 2012; 33: 165-170
- Predicting 6-month mortality risk of patients commencing dialysis treatment for end-stage kidney disease.Nephrol Dial Transplant. 2017; 32: 1558-1565
- Predialysis cardiovascular disease medication adherence and mortality after transition to dialysis.Am J Kidney Dis. 2016; 68: 609-618
- Association of slopes of estimated glomerular filtration rate with post-end-stage renal disease mortality in patients with advanced chronic kidney disease transitioning to dialysis.Mayo Clin Proc. 2016; 91: 196-207
- Blood pressure before initiation of maintenance dialysis and subsequent mortality.Am J Kidney Dis. 2017; 70: 207-217
- Transition of care from pre-dialysis prelude to renal replacement therapy: the blueprints of emerging research in advanced chronic kidney disease.Nephrol Dial Transplant. 2017; 32: ii91-ii98
- CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate [published correction appears in Ann Intern Med. 2011;155(6):408].Ann Intern Med. 2009; 150: 604-612
- Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.Stat Med. 2009; 28: 3083-3107
- A new nonparametric approach for baseline covariate adjustment for two-group comparative studies.Biometrics. 2008; 64: 1110-1116
- Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis.2nd ed. Springer International Publishing, Basel, Switzerland2015
- Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.Stat Med. 1996; 15: 361-387
- Application of shrinkage techniques in logistic regression analysis: a case study.Stat Neerl. 2001; 55: 76-88
- Assessing calibration of prognostic risk scores.Stat Methods Med Res. 2016; 25: 1692-1706
- Socioeconomic disparities in chronic kidney disease.Adv Chronic Kidney Dis. 2015; 22: 6-15
- Impact of non-adherence on renal and cardiovascular outcomes in US veterans.Am J Nephrol. 2015; 42: 151-157
- Impact of timing of nephrology referral and pre-ESRD care on mortality risk among new ESRD patients in the United States.Am J Kidney Dis. 2003; 41: 310-318
- A propensity analysis of late versus early nephrologist referral and mortality on dialysis.J Am Soc Nephrol. 2003; 14: 486-492
- Frailty and cognitive function in incident hemodialysis patients.Clin J Am Soc Nephrol. 2015; 10: 2181-2189
- Loss of independence in patients starting dialysis at 80 years of age or older [letter].N Engl J Med. 2009; 361: 1612-1613
- Functional status of elderly adults before and after initiation of dialysis.N Engl J Med. 2009; 361: 1539-1547
- Loss of executive function after dialysis initiation in adults with chronic kidney disease.Kidney Int. 2017; 91: 948-953
- Interaction of aging and chronic kidney disease.Semin Nephrol. 2009; 29: 497-503
- Impact of age and overt proteinuria on outcomes of stage 3 to 5 chronic kidney disease in a referred cohort.Clin J Am Soc Nephrol. 2010; 5: 1558-1565
- Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease.Arch Intern Med. 2011; 171: 110-118
- The survival benefit of “fistula first, catheter last” in hemodialysis is primarily due to patient factors.J Am Soc Nephrol. 2017; 28: 645-652
- The effect of predialysis fistula attempt on risk of all-cause and access-related death.J Am Soc Nephrol. 2017; 28: 613-620
Article Info
Publication History
Footnotes
Grant Support: This work was supported in part by grant U01-DK102163 from the National Institutes of Health (S.J.J., K.K.-Z., C.P.K.) and by resources from the U.S. Department of Veterans Affairs. The data reported here have been supplied in part by the U.S. Renal Data System. Support for the Department of Veterans Affairs/Centers for Medicare and Medicaid Services data is provided by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, and Veterans Affairs Information Resource Center (project numbers SDR 02-237 and 98-004). Dr Kalantar-Zadeh is supported by National Institute of Diabetes and Digestive and Kidney Diseases grant K24-DK091419 as well as philanthropic grants from Mr Harold Simmons, Mr Louis Chang, and Dr Joseph Lee. Dr Obi is supported by the Uehara Memorial Foundation Research Fellowship. Dr Rhee is supported by grants K23-DK102903 and R03-DK114642 from the National Institute of Diabetes and Digestive and Kidney Diseases. Dr Streja is supported by Department of Veterans Affairs grant IK2-CX001266-001. Dr Nguyen is supported by National Institute of Diabetes and Digestive and Kidney Diseases grant R01-DK092232.
Potential Competing Interests: Dr Kalantar-Zadeh has received honoraria and/or support from Abbott, AbbVie Inc, Alexion Pharmaceuticals, Inc, Amgen Inc, the American Society of Nephrology, AstraZeneca, Aveo Pharmaceuticals, Inc, Chugai Pharmaceutical Co, Inc, DaVita Inc, Fresenius Medical Care, Genetech, Inc, Haymarket Media Group, Hospira, Fresenius Kabi AG, Keryx Biopharmaceuticals, Inc, the National Institutes of Health, the National Kidney Foundation, Relypsa, Inc, Resverlogix Corp, Sanofi, Shire, Vifor Pharma, and ZS-Pharma, Inc, for work not related to this article. Dr Molnar has received consultation fees from Merck & Co, Inc, for work not related to this article. Dr Obi has received honoraria and/or support from Chugai Pharmaceutical Co and Ono Pharmaceutical Co, Inc, for work not related to this article. The other authors report no potential competing interests.
Data Previously Presented: This study was presented in part at Kidney Week 2017 in New Orleans, LA.
